[go: up one dir, main page]

PL2704704T3 - Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry - Google Patents

Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry

Info

Publication number
PL2704704T3
PL2704704T3 PL12730161T PL12730161T PL2704704T3 PL 2704704 T3 PL2704704 T3 PL 2704704T3 PL 12730161 T PL12730161 T PL 12730161T PL 12730161 T PL12730161 T PL 12730161T PL 2704704 T3 PL2704704 T3 PL 2704704T3
Authority
PL
Poland
Prior art keywords
probiotic bacteria
skin disorders
topical treatment
topical
probiotic
Prior art date
Application number
PL12730161T
Other languages
English (en)
Inventor
Heli Putaala
Arthur Ouwehand
Kirsti Tiihonen
Nina Rautonen
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Publication of PL2704704T3 publication Critical patent/PL2704704T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
PL12730161T 2011-05-03 2012-05-02 Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry PL2704704T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11164534 2011-05-03
EP12730161.2A EP2704704B1 (en) 2011-05-03 2012-05-02 Probiotic bacteria for the topical treatment of skin disorders
PCT/EP2012/058047 WO2012150269A1 (en) 2011-05-03 2012-05-02 Probiotic bacteria for the topical treatment of skin disorders

Publications (1)

Publication Number Publication Date
PL2704704T3 true PL2704704T3 (pl) 2019-04-30

Family

ID=46395577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12730161T PL2704704T3 (pl) 2011-05-03 2012-05-02 Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry

Country Status (6)

Country Link
US (4) US20140065209A1 (pl)
EP (1) EP2704704B1 (pl)
DK (1) DK2704704T3 (pl)
ES (1) ES2702490T3 (pl)
PL (1) PL2704704T3 (pl)
WO (1) WO2012150269A1 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
KR101166798B1 (ko) * 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
US9868957B2 (en) 2012-08-07 2018-01-16 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
GR1008308B (el) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Τοπικες φαρμακευτικες και ιατροτεχνολογικες συνθεσεις που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου ενυδατικου παραγοντα
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CN104957260B (zh) * 2014-03-07 2018-07-24 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
MY192494A (en) 2014-03-13 2022-08-24 Singapore Ze&Z Int Pte Ltd Vaginal composition and use thereof
GB201409541D0 (en) * 2014-05-29 2014-07-16 Univ Manchester Probiotic Bacteria
KR20170019427A (ko) 2014-06-17 2017-02-21 탑제닉스, 인크. Uv 차단을 위한 국소용 제형
US10584344B2 (en) 2014-06-17 2020-03-10 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
ES2864373T3 (es) 2014-12-23 2021-10-13 Ilya Pharma Ab Métodos para la cicatrización
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
BE1023416B1 (nl) 2016-02-26 2017-03-14 Chrisal Nv Synbiotisch preparaat
EP3222282A1 (en) * 2016-03-21 2017-09-27 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of psoriasis
AU2017240068B2 (en) 2016-03-31 2022-12-15 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
CA3018866C (en) 2016-03-31 2024-03-26 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
WO2017184992A1 (en) 2016-04-21 2017-10-26 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
ITUA20164065A1 (it) * 2016-06-01 2017-12-01 Probiotical Spa Composizioni in gel per applicazioni topiche a base di batteri, preparazione delle stesse e loro usi.
BE1024189B1 (nl) * 2016-10-28 2017-12-05 Yun NV Spuitbus met bacteriële species
AU2017365019A1 (en) 2016-11-23 2019-07-11 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101999693B1 (ko) 2017-06-13 2019-07-15 부산대학교 산학협력단 산성 환경에서 프로바이오틱스를 보호하는 프로바이오틱스 전달용 하이드로겔 제제 및 이를 포함하는 프로바이오틱스 전달용 조성물
KR101993270B1 (ko) * 2017-10-31 2019-06-26 (주)아모레퍼시픽 녹차 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
US12163135B2 (en) 2017-12-05 2024-12-10 BioPlx, Inc. Methods and compositions to prevent microbial infection
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
AU2019223439A1 (en) * 2018-02-24 2020-09-10 Clearskin Ltd Compositions, devices, systems, kits and methods for the treatment of a skin condition
KR102033333B1 (ko) * 2018-03-15 2019-10-17 부산대학교 산학협력단 프로바이오틱스 전달용 벤토나이트-하이드로겔 복합체 및 이를 포함하는 프로바이오틱스 전달용 조성물
MX2020012018A (es) 2018-05-11 2021-03-02 Forte Subsidiary Inc Composiciones para el tratamiento de condiciones de la piel.
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
KR20200064594A (ko) * 2018-11-29 2020-06-08 (주)아모레퍼시픽 녹차 유래 유산균을 포함하는 미세먼지에 의한 탈모 케어용 조성물
JP2022517754A (ja) 2019-01-04 2022-03-10 ラクトバイオ アー/エス 菌株、組成物および使用方法
CN112442457B (zh) * 2019-08-27 2022-07-22 大江生医股份有限公司 凝结芽孢杆菌或其代谢产物及其胃部保健的用途
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
CA3183350A1 (en) 2020-06-23 2021-12-30 Thomas M. Hitchcock Probiotic skin formulations
TWI750716B (zh) * 2020-06-30 2021-12-21 豐華生物科技股份有限公司 皮膚外用組成物及其用於製備改善皮膚疾病及皮膚發炎之組成物的用途
FR3118416B1 (fr) 2020-12-24 2023-11-17 Naos Inst Of Life Science Composition cosmetique apte a renforcer les jonctions serrees epidermiques pour la prevention et/ou le traitement de la dermatite atopique
TWI820499B (zh) * 2021-10-26 2023-11-01 豐華生物科技股份有限公司 益生菌液態培養物及其在改善皮膚相關病況上的用途
CN114717134B (zh) * 2021-11-15 2023-11-21 青岛蔚蓝生物股份有限公司 一株乳双歧杆菌及其在防治痤疮中的应用
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024062470A1 (en) 2022-09-21 2024-03-28 Moraz Medical Herbs (1989) Ltd. Dermal and cosmetic compositions
EP4450039A1 (en) 2023-04-17 2024-10-23 Texol S.R.L. Solid supports coated with or incorporating probiotics and metabolites of probiotic bacteria
EP4450042A1 (en) 2023-04-17 2024-10-23 Texol S.R.L. Solid supports coated with or incorporating probiotics and metabolites of probiotic bacteria

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
DE4221268C2 (de) 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
DE4221255C2 (de) 1992-06-26 1994-09-15 Lancaster Group Ag Phospholipide enthaltendes Kosmetikum
ATE202467T1 (de) 1993-10-22 2001-07-15 Smithkline Beecham Corp Neue zusammensetzung
AU3564299A (en) * 1998-04-17 1999-11-08 Board Of Regents For Oklahoma State University, The Propionibacterium p-63 for use in direct fed microbials for animal feeds
EP1110555A1 (fr) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
WO2003011261A1 (en) 2001-08-01 2003-02-13 Medlogic Global Limited Cyanoacrylate monomer-containing antibiotic formulation for topical use
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
JP5224807B2 (ja) * 2004-03-04 2013-07-03 イーエルシー マネージメント エルエルシー ラクトバチルス(Lactobacillus)抽出物による皮膚の処置方法
ITMI20041550A1 (it) * 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
KR20070091613A (ko) 2004-11-08 2007-09-11 그렌마크 파머수티칼스 엘티디. 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물
JP4800015B2 (ja) * 2005-11-22 2011-10-26 株式会社カロッツェリアジャパン 皮膚炎発症抑制のための微生物培養物並びにそれらを用いた製品
EP2032148A2 (en) * 2006-05-12 2009-03-11 Danisco A/S, Danisco Intellectual Capital Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist
US20080107699A1 (en) * 2006-10-25 2008-05-08 Mark Spigelman Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor
FR2920305B1 (fr) * 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
EP2141027A1 (en) 2008-07-03 2010-01-06 Kba-Giori S.A. Method and installation for applying foil material onto successive sheets
FR2938437B1 (fr) * 2008-11-19 2020-03-27 Société des Produits Nestlé S.A. Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
GB2466195A (en) * 2008-12-10 2010-06-16 Sharad Mohan Microbiotic Soap containing yoghurt bacteria
FR2942719B1 (fr) * 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees

Also Published As

Publication number Publication date
US20190099454A1 (en) 2019-04-04
US10555977B2 (en) 2020-02-11
DK2704704T3 (en) 2019-01-14
EP2704704B1 (en) 2018-09-26
EP2704704A1 (en) 2014-03-12
US20140065209A1 (en) 2014-03-06
US20160008412A1 (en) 2016-01-14
WO2012150269A1 (en) 2012-11-08
US20200376045A1 (en) 2020-12-03
ES2702490T3 (es) 2019-03-01

Similar Documents

Publication Publication Date Title
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
EP2575816A4 (en) COMBINATION THERAPY FOR HAIR DRESSES
IL225239A0 (en) Compounds for the treatment of acne and related diseases
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
ZA201205829B (en) Treatment of respiratory disorders
AU339607S (en) Medical device for treatment of sleep disorders
GB201202773D0 (en) Compositions for treatment of skin disorders
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1204573A1 (en) Treatment of inflammatory skin disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2681209A4 (en) COMPOUNDS AND METHODS FOR TREATING PAIN AND OTHER DISEASES
HK1186986A1 (zh) 治療皮膚病的方法
EP2723325A4 (en) NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
GB201107467D0 (en) Novel treatment of pain
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
EP2701702A4 (en) OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISEASES
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
AU2012902874A0 (en) Treatment of inflammatory skin disorders